UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

Alimentary pharmacology & therapeutics, 2020-06, Vol.51 (11), p.1149-1159

2020

Volltextzugriff (PDF)

Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients

The American journal of gastroenterology, 2020-04, Vol.115 (4), p.562-574

2020

Volltextzugriff (PDF)

Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States

Alimentary pharmacology & therapeutics, 2022-04, Vol.55 (7), p.828-835

2022

Volltextzugriff (PDF)

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

The New England journal of medicine, 2011-03, Vol.364 (13), p.1207-1217

2011

Volltextzugriff (PDF)

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

The New England journal of medicine, 2013-05, Vol.368 (20), p.1867-1877

2013

Volltextzugriff (PDF)

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Hepatology (Baltimore, Md.), 2017-08, Vol.66 (2), p.389-397

2017

Volltextzugriff (PDF)

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

Journal of hepatology, 2015-09, Vol.63 (3), p.564-572

2015

Volltextzugriff (PDF)

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Journal of hepatology, 2019-05, Vol.70 (5), p.1019-1023

2019

Volltextzugriff (PDF)

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

Journal of hepatology, 2014-12, Vol.61 (6), p.1238-1246

2014

Volltextzugriff (PDF)

Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals

Journal of viral hepatitis, 2023-06, Vol.30 (6), p.544-550

2023

Volltextzugriff (PDF)

Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET

Journal of hepatology, 2015-02, Vol.62 (2), p.286-293

2015

Volltextzugriff (PDF)

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients

Journal of hepatology, 2004-12, Vol.41 (6), p.935-942

2004

Volltextzugriff (PDF)

Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment

Gastroenterology (New York, N.Y. 1943), 2004-08, Vol.127 (2), p.485-492

2004

Volltextzugriff (PDF)

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

Virology (New York, N.Y.), 2013-09, Vol.444 (1), p.329-336

2013

Volltextzugriff (PDF)

Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials

PloS one, 2015-03, Vol.10 (3), p.e0121632-e0121632

2015

Volltextzugriff (PDF)

Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis

Expert opinion on pharmacotherapy, 2024-07, Vol.25 (11), p.1517-1523

2024

Volltextzugriff (PDF)

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score

Hepatology communications, 2020-07, Vol.4 (7), p.998-1011

2020

Volltextzugriff (PDF)

Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

Clinics in liver disease, 2017-02, Vol.21 (1), p.163-180

2017

Volltextzugriff (PDF)

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.751-761.e8

2015

Volltextzugriff (PDF)

Letter to the editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals

Hepatology (Baltimore, Md.), 2023-01, Vol.77 (1), p.E9-E10

2023

Volltextzugriff (PDF)

Baricitinib and primary biliary cholangitis

Journal of translational autoimmunity (Online), 2021-01, Vol.4, p.100107-100107, Article 100107

2021

Volltextzugriff (PDF)

Novel Therapies in Hepatic Encephalopathy

Clinics in liver disease, 2020-05, Vol.24 (2), p.303-315

2020

Volltextzugriff (PDF)

Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices

Alimentary pharmacology & therapeutics, 2020-08, Vol.52 (3), p.513-526

2020

Volltextzugriff (PDF)

1 – 25 von 1.014

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(925)
Mit Volltextzugriff
(827)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(623)
Life Sciences & Biomedicine
(569)
Humans
(479)
Female
(307)
Male
(283)
Middle Aged
(231)
Adult
(226)
Biological And Medical Sciences
(188)
Gastroenterology & Hepatology
(172)
Aged
(164)
Medical Sciences
(157)
Infectious Diseases
(87)
General & Internal Medicine
(80)
Antiviral Agents - Therapeutic Use
(77)
Medicine, General & Internal
(75)
Hepatitis
(72)
Hepatitis C
(72)
Treatment Outcome
(72)
Hepatitis C, Chronic - Drug Therapy
(69)
Patients
(67)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data

Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients

Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment

Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals

Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET

Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients

Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

Hepatitis B e antigen status and hepatitis B DNA levels in women of childbearing age with chronic hepatitis B infection screening for clinical trials

Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis

Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis‐4 Score

Management of Acute Hepatotoxicity Including Medical Agents and Liver Support Systems

Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid

Letter to the editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals

Baricitinib and primary biliary cholangitis

Novel Therapies in Hepatic Encephalopathy

Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices

Suchergebnisse filtern